FDA delays review of AZ's Brilinta

AstraZeneca said today that the FDA has extended the time to complete its review of its application for Brilinta (ticagrelor). The PDUFA date has been moved from September 16 to December 16. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.